Xbrane Biopharma Management
Management criteria checks 4/4
Xbrane Biopharma's CEO is Martin Amark, appointed in Jan 2015, has a tenure of 9.33 years. total yearly compensation is SEK3.36M, comprised of 77% salary and 23% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth SEK36.05K. The average tenure of the management team and the board of directors is 6 years and 5 years respectively.
Key information
Martin Amark
Chief executive officer
kr3.4m
Total compensation
| CEO salary percentage | 77.0% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 6yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04
We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)
Mar 24Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings
Mar 02Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price
Feb 10We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth
Jan 12What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?
Dec 16Insider Buying: The Xbrane Biopharma AB (publ) (STO:XBRANE) Head of Manufacturing & Supply Chain Just Bought 50% More Shares
Nov 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | kr3m | kr3m | -kr322m |
| Sep 30 2023 | n/a | n/a | -kr285m |
| Jun 30 2023 | n/a | n/a | -kr246m |
| Mar 31 2023 | n/a | n/a | -kr189m |
| Dec 31 2022 | kr5m | kr2m | -kr169m |
| Sep 30 2022 | n/a | n/a | -kr146m |
| Jun 30 2022 | n/a | n/a | -kr147m |
| Mar 31 2022 | n/a | n/a | -kr172m |
| Dec 31 2021 | kr4m | kr2m | -kr183m |
| Sep 30 2021 | n/a | n/a | -kr213m |
| Jun 30 2021 | n/a | n/a | -kr219m |
| Mar 31 2021 | n/a | n/a | -kr215m |
| Dec 31 2020 | kr3m | kr1m | -kr218m |
| Sep 30 2020 | n/a | n/a | -kr222m |
| Jun 30 2020 | n/a | n/a | -kr210m |
| Mar 31 2020 | n/a | n/a | -kr204m |
| Dec 31 2019 | kr2m | kr1m | -kr188m |
| Sep 30 2019 | n/a | n/a | -kr154m |
| Jun 30 2019 | n/a | n/a | -kr56m |
| Mar 31 2019 | n/a | n/a | -kr40m |
| Dec 31 2018 | kr1m | kr1m | -kr13m |
| Sep 30 2018 | n/a | n/a | kr30k |
| Jun 30 2018 | n/a | n/a | -kr69m |
| Mar 31 2018 | n/a | n/a | -kr45m |
| Dec 31 2017 | kr1m | kr919k | -kr45m |
Compensation vs Market: Martin's total compensation ($USD308.05K) is about average for companies of similar size in the Swedish market ($USD240.80K).
Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.
CEO
Martin Amark (43 yo)
9.3yrs
Tenure
kr3,360,000
Compensation
Mr. Martin Amark serves as Chief Executive Officer of Xbrane Biopharma AB (publ) and served as its Head of Investor Relation since February 14, 2019. He has experience from Bain & Co as a Management Consul...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 9.3yrs | kr3.36m | 0.012% SEK 36.1k | |
| COO, Head of Biosimilars & Deputy CEO | 9.3yrs | kr1.79m | 0.0076% SEK 22.2k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | 16.3yrs | no data | no data | |
| CFO & Head of Investor Relations | 3.3yrs | no data | 0.00098% SEK 2.9k | |
| Chief Technology Officer | 10.3yrs | no data | 0.0022% SEK 6.3k | |
| Head of Human Resources | 3.4yrs | no data | 0% SEK 0 | |
| Head of Clinical Affairs | 6.7yrs | no data | 0.000030% SEK 87.4 | |
| Head of Regulatory Affairs & Quality Assurance | 5.3yrs | no data | 0% SEK 0 | |
| Head of Manufacturing & Supply Chain | 5.3yrs | no data | 0.00091% SEK 2.7k | |
| Head of Intellectual Property | no data | no data | no data | |
| Chief Business Officer | 4yrs | no data | no data |
6.0yrs
Average Tenure
46yo
Average Age
Experienced Management: XBRANE's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4yrs | kr435.00k | 0.00026% SEK 757.2 | |
| Independent Director | 9.3yrs | kr360.00k | 0.00098% SEK 2.9k | |
| Independent Director | 5yrs | kr460.00k | 0.00026% SEK 757.2 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5yrs | kr360.00k | no data | |
| Independent Director | 9.3yrs | kr360.00k | 0.0017% SEK 4.9k | |
| Independent Director | 2yrs | kr385.00k | 0.00016% SEK 465.9 | |
| Independent Chairman of the Board | 6.1yrs | kr820.00k | 0.0046% SEK 13.4k |
5.0yrs
Average Tenure
62yo
Average Age
Experienced Board: XBRANE's board of directors are considered experienced (5 years average tenure).